ShanghaiJune 9, 2026 /PRNewswire/ — Today, Siemens Healthineers’ first domestically produced dual-source photon-counting CT, the NAEOTOM Alpha.Pro, received market approval from the National Medical Products Administration (NMPA). This milestone not only marks Siemens Healthineers’ pioneering completion of the “import + domestic” dual-track strategic layout for this cutting-edge technology but also signifies that this CT imaging technology will further integrate deeply into China’s local industrial chain, supporting high-quality innovation and supply chain upgrades for China’s high-end medical equipment. The domestically produced dual-source photon-counting CT will be manufactured at Siemens Healthineers’ Shanghai R&D and production base in the future.
The approval of the domestically produced dual-source photon-counting CT NAEOTOM Alpha.Pro represents another significant achievement in Siemens Healthineers’ deepening of its China strategy. Unlike a simple production transfer, this project aims to accelerate and enhance the accessibility and collaborative efficiency of high-end precision imaging equipment in China by establishing a mechanism for deep integration of global technological innovation with local clinical needs, supply chains, and industrial ecosystems. To this end, Siemens Healthineers has built a full-chain localization operation system, including the formation of a local product line team for photon-counting CT, covering the entire lifecycle from product definition, R&D, registration, to service. Simultaneously, a high-standard, specialized production workshop has been established at Siemens Healthineers’ Shanghai base. This not only enhances the resilience and security of the global supply chain but also drives local supply chain partners to move up the value chain, promoting the industry’s continuous development towards intelligence and high-end capabilities.
Thanks to its outstanding originality and clinical value, the NAEOTOM Alpha.Pro entered the National Medical Products Administration’s Innovative Medical Device Special Review Process in October 2025, reflecting that its technological innovation meets the relevant requirements for innovative medical devices and that the registration review process is being advanced in accordance with innovative medical device standards.
As a new domestically produced member of Siemens Healthineers’ global first photon-counting CT NAEOTOM Alpha family, the NAEOTOM Alpha.Pro inherits the technological advantages of the platform while adding multi-material, multi-energy compartment clinical applications. It will provide technical support for the diagnosis and treatment of cardiovascular, respiratory, oncological, and metabolic diseases. To date, the NAEOTOM Alpha has performed over 3.5 million scans worldwide, with more than 1,200 papers published, and has been installed and used in 22 provinces and cities across China. Its application provides a reference for clinical practice and scientific research in the field of imaging technology. It is expected that within 2026, Siemens Healthineers’ second domestically produced photon-counting CT product will also receive market approval. With the addition of domestic models, Siemens Healthineers is driving the further application of photon-counting CT-related technologies in China’s medical imaging field.
Disclaimer: This article is a press release intended to introduce the progress of product registration and corporate developments. It does not constitute any commercial promotion or product usage advice.
About Siemens Healthineers
Pioneering breakthroughs in healthcare. For everyone. Everywhere. Siemens Healthineers is a leading global medical technology company, providing medical devices, solutions, and services, with operations in over 180 countries and direct business in more than 70 countries and regions. Siemens Healthineers is comprised of Siemens Healthineers AG (listed on the Frankfurt Stock Exchange, ticker: SHL) and its subsidiaries. The company is committed to improving access to high-quality healthcare while combating life-threatening diseases. Siemens Healthineers’ business covers areas such as medical imaging, in-vitro diagnostics, cancer care, and minimally invasive therapies, and strengthens each of its businesses through digital technologies and artificial intelligence. As of fiscal year 2025 (ending September 30, 2025), Siemens Healthineers employed approximately 74,000 people worldwide and generated revenue of around €23.4 billion. For more information, please visit Siemens Healthineers’ official website: www.siemens-healthineers.com